Clinical Trials Logo

Clinical Trial Summary

This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in up to approximately 340 subjects ≥6 months of age with MC. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study.


Clinical Trial Description

This is a Phase 3 multi-center, randomized, double-blind, vehicle-controlled, parallel group study to be conducted in approximately 340 subjects with MC. After obtaining informed consent/assent, subjects who satisfy entry criteria will be randomized 2:1 (active:vehicle). Subjects receiving current treatment for MC at the time of the Screening Visit will enter a wash out period of up to 14 days prior to randomization. Subjects or their caregivers will apply SB206 12% or Vehicle Gel once daily for a minimum of 4 weeks and up to 12 weeks to all lesions identified at Baseline and new treatable lesions that arise during the course of the study. Subjects or their caregivers will continue to treat the area until the next scheduled visit even if the lesion(s) clear. If the investigator determines all lesions are cleared at a clinic visit, the treatment may stop. Subjects will visit the clinic at Screening/Baseline, Week 2, Week 4, Week 8, Week 12. In addition, subjects will be seen in the clinic for a safety follow-up at Week 24. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03927703
Study type Interventional
Source Novan, Inc.
Contact
Status Completed
Phase Phase 3
Start date June 13, 2019
Completion date February 3, 2020

See also
  Status Clinical Trial Phase
Completed NCT03017846 - Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 Phase 2
Recruiting NCT05937672 - Cold Atmospheric Plasma Device Extension Study Phase 3
Completed NCT04535531 - A Phase 3 Molluscum Contagiosum Efficacy and Safety Study Phase 3
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT05897112 - Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum Phase 1
Withdrawn NCT05536882 - MC RCT - BPO vs Adapalene Phase 3
Completed NCT03377790 - Cantharidin Application in Molluscum Patients-1 Phase 3
Completed NCT01348386 - Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum Phase 2/Phase 3
Completed NCT05634460 - Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum Phase 1
Completed NCT03186378 - Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. Phase 2
Completed NCT03927716 - A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) Phase 3
Recruiting NCT04476186 - The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children N/A
Completed NCT02665260 - Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03436615 - A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum Phase 2
Recruiting NCT02759900 - Using a Cold Atmospheric Plasma Device to Treat Skin Disorders N/A
Completed NCT05680181 - Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
Completed NCT03077750 - A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum Phase 2
Terminated NCT02024581 - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03377803 - Cantharidin Application in Molluscum Patients Phase 3
Withdrawn NCT03336372 - Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients Early Phase 1